These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31396693)

  • 1. Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT).
    Drach M; Papageorgiou K; Maul JT; Djamei V; Yawalkar N; Häusermann P; Anzengruber F; Navarini AA
    Arch Dermatol Res; 2019 Dec; 311(10):753-760. PubMed ID: 31396693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Warren RB; Mrowietz U; von Kiedrowski R; Niesmann J; Wilsmann-Theis D; Ghoreschi K; Zschocke I; Falk TM; Blödorn-Schlicht N; Reich K
    Lancet; 2017 Feb; 389(10068):528-537. PubMed ID: 28012564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.
    Maul JT; Djamei V; Kolios AGA; Meier B; Czernielewski J; Jungo P; Yawalkar N; Mainetti C; Laffitte E; Spehr C; Anliker M; Streit M; Augustin M; Rustenbach S; Conrad C; Hafner J; Boehncke WH; Borradori L; Gilliet M; Itin P; French LE; Häusermann P; Navarini AA
    Dermatology; 2016; 232(6):640-647. PubMed ID: 28076860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients.
    Erduran F; Emre S; Hayran Y; Adışen E; Polat AK; Üstüner P; Öztürkcan S; Öztürk P; Ermertcan AT; Selçuk LB; Aksu EK; Akbaş A; Kalkan G; Demirseren D; Kartal SP; Topkarcı Z; Kılıç A; Yaldız M; Aytekin S; Hızlı P; Gharehdaghi S; Borlu M; Işık L; Botsalı BR; Solak EÖ; Albayrak H; Gönülal M; Balcı DD; Polat M; Daye M; Ataseven A; Yıldız S; Özer İ; Zorlu Ö; Doğan S; Erdemir VA; Dikicier BS
    Arch Dermatol Res; 2024 May; 316(6):278. PubMed ID: 38796658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.
    Tournier A; Khemis A; Maccari F; Reguiai Z; Bégon E; Fougerousse AC; Amy de la Breteque M; Beneton N; Parier J; Boyé T; Avenel-Audran M; Girard C; Pallure V; Perrot JL; Bastien M; Mahé E; Beauchet A;
    Ann Dermatol Venereol; 2019 Feb; 146(2):106-114. PubMed ID: 30704943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study.
    Anzengruber F; Augustin M; Radtke MA; Thaci D; Yawalkar N; Streit M; Reich K; Drach M; Sorbe C; French LE; Mrowietz U; Maul JT; Itin PH; Navarini AA
    Acta Derm Venereol; 2019 Sep; 99(10):871-877. PubMed ID: 31099404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A; Tan E; Ilchyshyn A; Berth-Jones J
    Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.
    Chládek J; Simková M; Vanecková J; Hroch M; Chládkova J; Martínková J; Vávrová J; Beránek M
    Eur J Clin Pharmacol; 2008 Apr; 64(4):347-55. PubMed ID: 18163165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis.
    Yan K; Zhang Y; Han L; Huang Q; Zhang Z; Fang X; Zheng Z; Yawalkar N; Chang Y; Zhang Q; Jin L; Qian D; Li X; Wu M; Xu Q; Zhang X; Xu J
    JAMA Dermatol; 2019 Mar; 155(3):327-334. PubMed ID: 30698628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial.
    Radmanesh M; Rafiei B; Moosavi ZB; Sina N
    Int J Dermatol; 2011 Oct; 50(10):1291-3. PubMed ID: 21950300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S; Krishna V; Kanwar AJ
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis.
    Dogra S; Singh N; Kumar S; Narang T; Handa S
    Dermatol Ther; 2022 Aug; 35(8):e15656. PubMed ID: 35730664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The METOP Study: Further Evidence for the Use of Subcutaneous Methotrexate in Psoriasis.
    Morgado-Carrasco D; Fustà-Novell X; Riera Monroig J; Mascaró Galy JM
    Actas Dermosifiliogr; 2017 Nov; 108(9):865-866. PubMed ID: 28583269
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis.
    Yesudian PD; Leman J; Balasubramaniam P; Macfarlane AW; Al-Niaimi F; Griffiths CE; Burden AD; Warren RB
    J Drugs Dermatol; 2016 Mar; 15(3):345-9. PubMed ID: 26954320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA.
    Al-Dabagh A; Davis SA; Kinney MA; Huang K; Feldman SR
    Am J Clin Dermatol; 2013 Jun; 14(3):155-61. PubMed ID: 23575550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy of psoriasis: methotrexate.
    Kozub P; Simaljakova M
    Bratisl Lek Listy; 2011; 112(7):390-4. PubMed ID: 21744734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.